伊利尤单抗(Ianalumab) - 药物靶点：BAFF-R_在研适应症：干燥综合征，系统性红斑狼疮，免疫性血小板减少症_专利_临床

概要

基本信息

药物类型

单克隆抗体

别名

NOV-5、VAY-736、VAY736

靶点

BAFF-R

作用方式

抑制剂

作用机制

BAFF-R抑制剂(B细胞活化因子受体抑制剂)

治疗领域

免疫系统疾病眼部疾病口颌疾病+ [6]

在研适应症

干燥综合征系统性红斑狼疮免疫性血小板减少症+ [11]

非在研适应症

难治性慢性淋巴细胞白血病化脓性汗腺炎特发性肺纤维化+ [4]

原研机构

MorphoSys AG

在研机构

Novartis Pharmaceuticals Corp.

Novartis Pharmaceuticals Canada, Inc.Novartis Pharma Stein AG

+ [7]

非在研机构-

权益机构

Novartis AG

MorphoSys AG

最高研发阶段申请上市

首次获批日期-

最高研发阶段(中国)申请上市

特殊审评突破性疗法 (美国)、孤儿药 (美国)、快速通道 (美国)

登录后查看时间轴

结构/序列

Sequence Code 155090L

来源: *****

Sequence Code 155096H

来源: *****

关联

34

项与伊利尤单抗相关的临床试验

NCT07421167

/ Not yet recruiting临床2期

A Phase 2 Open-label Study to Evaluate the Tolerability of Ianalumab (VAY736) With Investigator's Choice Thrombopoietin Receptor Agonist (IC TPO-RA) in Patients With Primary Immune Thrombocytopenia (ITP) Previously Treated With at Least One Treatment (VAY2EXPLORE)

The purpose of this study is to investigate the tolerability of ianalumab (9 mg/kg) with investigator's choice thrombopoietin receptor agonist (IC TPO-RA) in participants diagnosed with primary immune thrombocytopenia (ITP) who have been treated with at least one but no more than four prior treatments, and with no change in IC TPO-RA dose in at least the last 14 days prior to the start of ianalumab.

开始日期2026-06-30

申办/合作机构

Novartis Pharmaceuticals Canada, Inc.

NCT07039422

/ Recruiting临床2期

A Phase 2 Study of Ianalumab in Adults With Primary Immune Thrombocytopenia (ITP) and Warm-antibody Autoimmune Hemolytic Anemia (wAIHA) Who Have Previously Benefited From Ianalumab.

This study is intended to explore the efficacy and safety of a second course of ianalumab after experiencing treatment failure in the pivotal Primary Immune Thrombocytopenia (ITP) trials (CVAY736I12301, CVAY736Q12301) and after loss of durable response in the pivotal Warm Autoimmune Hemolytic Anemia (wAIHA) trial (CVAY736O12301).

开始日期2026-04-27

申办/合作机构

Novartis Pharmaceuticals Canada, Inc.

NCT06711887

/ Recruiting临床3期

An Open-label Extension Study to Assess the Efficacy and Safety of Ianalumab With or Without Study Treatment Withdrawal in Adult Participants With Lupus Nephritis Who Have Completed Study Treatment in the CVAY736K12301 Core Study (SIRIUS-LN Extension)

The purpose of this 2-year extension study is the evaluation of the efficacy and safety
1. after study treatment withdrawal in patients with lupus nephritis (LN) who achieved response (complete renal response [CRR] or partial renal response [PRR]) on double-blind treatment at the end of the SIRIUS-LN core study, and
2. of open-label ianalumab 300 mg treatment in patients who, at the end of the SIRIUS-LN core study, were either already receiving ianalumab open-label treatment or did not meet CRR/PRR criteria on double-blind treatment at the end of the SIRIUS-LN core study.

开始日期2025-05-19

申办/合作机构

Novartis Pharmaceuticals Canada, Inc.

100 项与伊利尤单抗相关的临床结果

登录后查看更多信息

100 项与伊利尤单抗相关的转化医学

登录后查看更多信息

100 项与伊利尤单抗相关的专利（医药）

登录后查看更多信息

22

项与伊利尤单抗相关的文献（医药）

2026-06-01·CURRENT OPINION IN IMMUNOLOGY

Clinical trials and new therapies in Sjögren’s disease

Review

作者: Grader-Beck, Thomas ; Salas, Antonio ; Patel, Vishal

Despite major advances in understanding Sjögren's disease (SjD), no approved disease-modifying therapies have been approved. Management remains largely symptomatic with the use of off-label immunomodulators for systemic features. This gap highlights the substantial unmet need for targeted treatment. Encouragingly, the therapeutic landscape is shifting. Several phase 2 trials have shown meaningful efficacy signals, and for the first time, phase 3 programs with ianalumab and telitacicept have demonstrated positive outcomes, particularly when systemic activity is assessed using the EULAR Sjögren's Syndrome Disease Activity Index. These successes reflect both the maturation of the therapeutic pipeline and important refinements in trial design. Insights from earlier negative studies have underscored the importance of enrolling patients with active disease, incorporating biomarker-defined subgroups, and development of composite endpoints that integrate systemic, symptomatic, and functional domains. Together, these developments suggest that SjD may finally be approaching an era of effective, disease-modifying therapy.

2026-03-01·ANNALS OF THE RHEUMATIC DISEASES

B cell depletion and BAFF receptor blockade with ianalumab (VAY736) for the treatment of moderate-to-severe systemic lupus erythematosus: a phase 2 randomised, double-blind, placebo-controlled trial with subsequent open-label treatment

Article

作者: Tarr, Tunde ; Ignatenko, Stanislav ; Koolvisoot, Ajchara ; Leszczynski, Piotr ; Ciferská, Hana ; Rojkovich, Bernadette ; Kaneko, Yuko ; Lee, Shin-Seok ; Sips, Carole ; Zotkin, Eugeny ; López, Berta Paula Magallares ; Romanowska-Próchnicka, Katarzyna ; Kodera, Masanari ; Wojciechowski, Rafal ; Hoi, Alberta ; Okada, Masato ; Lau, Carol ; Kaneko, Hiroshi ; Cortés-Hernández, Josefina ; Lie, Dai ; Avrameas, Alexandre ; Narongroeknawin, Pongthorn ; Finzel, Stephanie ; Chen, Yi-Hsing ; Vishneva, Elena ; Shen, Nan ; Ghanshani, Swati Aashish ; Oliver, Stephen John ; Agmon-Levin, Nancy ; Sun, Lingyun ; Viallard, Jean-Francoise ; Cheng-Chung, Wei J ; Gordienko, Alexander ; Mysler, Eduardo ; Lan, Joung-Liang

OBJECTIVES:

B cell depletion or B cell activating factor (BAFF) blockade has shown benefits in systemic lupus erythematosus (SLE). We compared ianalumab, a monoclonal antibody targeting BAFF receptor (BAFF-R)-expressing B cells to lyse B cells and block BAFF-R, with placebo for SLE treatment combined with standard therapies.

METHODS:

Patients with active SLE were randomised (1:1) to monthly subcutaneous ianalumab 300 mg or placebo. The primary outcome was a composite of SLE Responder Index (SRI)-4 at week 28 in patients successfully achieving corticosteroid (CS) tapering criteria. Patients subsequently received open-label (OL) ianalumab until week 48, followed by exploratory assessments at week 52 and off-treatment to week 68. Safety monitoring continued until B cell recovery. This report describes interim analyses conducted on the week 68 dataset.

RESULTS:

Sixty-seven patients were randomised and received blinded treatments until week 28. The primary composite endpoint was more frequently achieved with ianalumab vs placebo: 15/34 (44.1%) vs 3/33 (9.1%), with responses sustained to week 52 and replicated by placebo transitioned to OL ianalumab: 15/33 (45.5%) and 13/32 (40.6%). Positive treatment effects were consistently observed across other lupus disease activity outcomes (SRI-6, Definition of Remission in SLE, Lupus Low Disease Activity State, flare reduction, and CS use) at week 28, with clinical benefits until weeks 52 and 68. Ianalumab was not associated with increased serious adverse events or serious infections. Nonserious local injection site reactions occurred more frequently with ianalumab.

CONCLUSIONS:

At week 28, reduced disease activity was observed in patients with SLE receiving ianalumab plus standard therapies compared with those receiving standard therapies alone, with sustained benefits with further treatment until 1 year, which was well tolerated.

2026-01-01·CURRENT OPINION IN RHEUMATOLOGY

Advances in the diagnosis and treatment of Sjögren disease

Review

作者: Karampela, Asimina I. ; Tsironis, Christos ; Mavragani, Clio P.

Purpose of review:

Sjögren disease (SjD) constitutes a diagnostic and therapeutic challenge due to its clinical heterogeneity and complex pathophysiology. This review synthesizes recent advances in diagnostics, disease stratification, and targeted therapies, highlighting their potential to optimize patient care.

Recent findings:

Emerging diagnostic approaches include advanced salivary, lacrimal, and serum biomarkers, refinements of established diagnostic tools, role of specific autoantibodies, and AI-assisted histopathology, improving early detection and risk stratification, particularly for lymphoma-prone phenotypes. Novel immunological insights have enabled phenotype-based classification, guiding the development of targeted therapies against B-cell pathways, cytokines, and co-stimulatory molecules with several agents (e.g., belimumab, ianalumab, telitacicept) showing promise in reducing disease activity scores.

Summary:

Recent advances provide a framework for precision medicine in SjD, integrating molecular and imaging biomarkers into patient selection and treatment monitoring. Clinically, this could enable earlier diagnosis, individualized risk assessment, and tailored therapy. Research priorities now include validating diagnostic innovations in diverse populations, elucidating phenotype-specific mechanisms, and conducting adequately powered, biomarker-driven trials to optimize therapeutic efficacy.

264

项与伊利尤单抗相关的新闻（医药）

2026-04-25

·小红书

干燥综合征治疗迈入新阶段：B细胞靶向治疗

许多干燥综合征患者长期依赖人工泪液和免疫抑制剂来“维持”病情：口干、眼干反复出现，症状似乎有所缓解，但疾病进程却难以真正控制。其根本原因在于——传统治疗多停留在“压制炎症”层面，而未能从源头纠正免疫系统的异常失衡。但这几年，随着对发病机制的深入认识，一场围绕B细胞的精准治疗革命，正在悄然发生。 ⸻ 🎯 精准医疗的关键突破 01 破局武器一：双靶点“精准断粮”策略传统B细胞治疗，更像是“单点拦截”，效果有限。而新一代双靶点药物，则是直接切断B细胞生存的“供给系统”。代表药物就是——泰它西普 👉 同时靶向BAFF（BLyS）和APRIL两大关键因子 👉 从源头抑制B细胞异常存活和分化 👉 实现更全面的免疫调控 📊 临床研究显示：治疗24周后，患者ESSDAI评分显著下降，部分患者唾液分泌功能得到客观改善。这意味着，它不仅缓解症状，还有望影响疾病进程。目前，该药在干燥综合征领域的应用正在加速推进，有望成为这一疾病领域的重要突破口。 ⸻ 02 破局武器二：“清除+抑制”双机制升级如果说双靶点是“断供”，那么另一类策略则更进一步——“边清除、边控制”。代表药物：Ianalumab 👉 一方面通过ADCC效应直接清除致病B细胞 👉 另一方面阻断BAFF-R信号，防止新生B细胞补充这种“双管齐下”的设计，避免了传统治疗中常见的“反弹”问题。 📈 临床数据显示：患者疾病活动评分明显改善，且起效时间较快，为中重度患者提供了更有力的选择。 ⸻ 03 破局武器三：信号通路“精准拦截” 除了直接作用于B细胞表面，新一代小分子药物开始深入“细胞内部”，干预关键信号通路。代表方向： 👉 BTK抑制剂（如 Remibrutinib） 👉 SYK等通路抑制剂这些药物通过阻断B细胞受体（BCR）下游信号，精准调控免疫反应。 ⚡ 意义在于： ✔ 为不同阶段患者提供分层治疗选择 ✔ 可能减少传统免疫抑制带来的副作用 ✔ 实现更精细的个体化治疗 ⸻ 🌿 写在最后干燥综合征的治疗，正在从“对症缓解”迈向“机制干预”。以B细胞为核心的新靶点不断涌现，让过去“难以逆转”的疾病状态，开始出现改变的可能。当然，这些新药仍在不断积累证据，如何选择、何时使用，依然需要专科医生评估。但可以确定的是—— 👉 一个更精准、更有针对性的治疗时代，已经在路上了。#干燥综合征 #生物制剂

2026-04-24

·守衡生物 ShownBio

GLUD1研发热潮下的暗礁：脱靶风险如何破局？

前言在生物医药领域，每个新靶点的发现都像打开一扇通往疾病治疗的新大门。近年来，GLUD1（谷氨酸脱氢酶1）凭借在癌症、神经疾病、肌肉疾病等多个领域的“多面潜力”，迅速成为研发热点。但越是热门的靶点，越需要警惕隐藏的风险。今天就想以行业观察者和从业者的双重身份，和大家好好聊聊：GLUD1研发的核心痛点在哪？为什么脱靶检测才是破局关键？一、为什么GLUD1能成为研发热门？ GLUD1之所以能刷屏研发圈，核心在于它不是“单一功能靶点”，而是横跨代谢、免疫、神经三大系统的关键枢纽。这几年的多项重磅研究，更是直接奠定了它的研发价值【1】【2】：图【1】图【2】抗肿瘤领域：打破免疫治疗耐药困局 2025 年 12月24日，徐州医科大学吕凌教授团队联合南京医科大学第一附属医院在国际顶级期刊《Cell》正式发表《Tumor-produced ammonia is metabolized by regulatory T cells to further impede anti-tumor immunity》研究论文。这篇研究首次从代谢 - 免疫 - 空间异质性交叉维度，阐明了肿瘤来源氨通过调控调节性 T 细胞（Treg 细胞）功能、驱动免疫治疗耐药的全新机制，并锁定 GLUD1 为核心干预靶点，为抗肿瘤联合免疫治疗提供了极具转化潜力的新策略【3】。图【3】 2. 神经与肌肉疾病：带来全新治疗方向在神经系统中，GLUD1参与谷氨酸代谢，直接影响突触传递和神经环路平衡，其低表达与胶质母细胞瘤患者不良预后相关，功能异常还可能关联自闭症、精神分裂症等神经发育障碍；在肌肉疾病领域，2025年7月的新研究证实，抑制GLUD1能显著增强杜氏肌营养不良症（DMD）模型小鼠的肌肉力量和协调性，给全球DMD患者带来了新希望【4】。图【4】二、必须警惕：热门靶点背后的“脱靶陷阱” 聊完潜力，再来说说大家最关心的风险——越是“多面手”靶点，脱靶风险越高。这不是危言耸听，而是GLUD1的自身特性决定的。结合我们守衡生物的检测实践，总结了三个核心风险点： 1. 组织分布太广：治疗靶点可能变“毒性靶点” GLUD1不只是在病变组织中表达，在肝脏、大脑、肌肉等正常组织中都广泛存在，且承担着关键生理功能：肝脏中参与尿素循环清除氨，大脑中调控谷氨酸水平，肌肉中支持能量代谢。如果针对肿瘤研发的GLUD1抑制剂“脱靶”作用于肝脏，可能导致氨代谢障碍引发高氨血症；作用于大脑，则可能干扰神经环路，导致认知障碍或情绪异常——这些都是临床试验失败的“致命原因”。就像之前布鲁顿酪氨酸激酶抑制剂伊布替尼，就是因为脱靶效应引发心房颤动、高血压等不良反应，而特异性更高的阿卡替尼则无此类问题，这充分说明靶点特异性对药物安全性的关键影响。 2. 功能网络复杂：牵一发可能动全身 GLUD1的功能不是孤立的，而是串联起多个关键通路：免疫领域连接尿素循环与多胺代谢，代谢领域参与谷氨酰胺回补三羧酸循环，神经领域与谷氨酸受体协同调控突触稳态。这种“通路交叉性”意味着，药物抑制GLUD1阻断肿瘤免疫抑制的同时，可能也会抑制正常细胞的谷氨酰胺代谢，导致红细胞生成减少（引发贫血）或肠道上皮细胞增殖受阻（引发肠道损伤）。这些“脱靶关联效应”在临床前很容易被忽视，最终引发临床阶段的安全性危机。 3. 研发类型多样：不同药物风险各有侧重目前针对GLUD1的研发药物涵盖小分子抑制剂、ADC、肽类药物等，不同类型药物的脱靶风险差异很大： • 小分子抑制剂：易通过血脑屏障，需重点警惕中枢神经系统脱靶毒性； • ADC药物：若抗体交叉结合肝脏、肾脏等组织的GLUD1，可能引发脱靶性细胞毒性； • 肽类药物：虽特异性较高，但可能与GLUD2（GLUD1的同源蛋白）发生交叉反应。要知道，GLUD2是人与猿特异的重复基因，主要在肾脏表达，与GLUD1在表达模式、分子功能上差异显著，一旦交叉抑制就可能导致肾脏代谢异常。图片来源：【https://www.cell.com/cms/10.1016/j.devcel.2024.07.015/asset/94a9cfcb-cb38-43d1-b31f-30ddc2e28174/main.assets/fx1.jpg】三、GLUD1药物研发，安全才能走得远从《Cell》的抗肿瘤研究到DMD的治疗突破，GLUD1的研发价值正在不断被验证，但“多面手”靶点的特性决定了其研发之路必然充满“暗礁”。忽视脱靶风险的研发，就像盲人摸象，即便短期内看到疗效希望，后期也可能因安全性问题功亏一篑。守衡生物深耕药物安全性评价领域，专注脱靶检测技术研发，就是希望成为药企研发路上的“排雷专家”。我们相信，只有在临床前阶段充分排查脱靶风险，才能让药物在临床试验中走得更稳、更远，最终为患者带来有效且安全的治疗方案。参考文献【1】 Dai J, Patzke C, Liakath-Ali K, Seigneur E, Südhof TC. GluD1 is a signal transduction device disguised as an ionotropic receptor. Nature. 2021 Jul;595(7866):261-265. doi: 10.1038/s41586-021-03661-6. Epub 2021 Jun 16. Erratum in: Nature. 2025 Jun;642(8069):E27. doi: 10.1038/s41586-025-09146-0. PMID: 34135511; PMCID: PMC8776294. 【2】 Zhang J, Sjøberg KA, Gong S, Wang T, Li F, Kuo A, Durot S, Majcher A, Ardicoglu R, Desgeorges T, Mann CG, Soro Arnáiz I, Fitzgerald G, Gilardoni P, Abel ED, Kon S, Olivares-Villagómez D, Zamboni N, Wolfrum C, Hornemann T, Morscher R, Tisch N, Ghesquière B, Kopf M, Richter EA, De Bock K. Endothelial metabolic control of insulin sensitivity through resident macrophages. Cell Metab. 2024 Nov 5;36(11):2383-2401.e9. doi: 10.1016/j.cmet.2024.08.008. Epub 2024 Sep 12. PMID: 39270655. 【3】 Gu J, Li Y, Chen Q, Song Z, Qian Q, Liang Y, Huang T, Qiao L, Li X, Yu M, Liu M, Zhou J, Shao Q, Xu X, Zeiser R, Lu L. Tumor-produced ammonia is metabolized by regulatory T cells to further impede anti-tumor immunity. Cell. 2025 Dec 24:S0092-8674(25)01369-8. doi: 10.1016/j.cell.2025.11.034. Epub ahead of print. PMID: 41448182. 【4】 Lin, J., Jin, M., Yang, D. et al. Adenine base editing-mediated exon skipping restores dystrophin in humanized Duchenne mouse model. Nat Commun 15, 5927 (2024). https://doi.org/10.1038/s41467-024-50340-x 关于我们守衡⽣物是⼀家专注于抗体特异性分析领先解决⽅案的⽣物技术公司，通过⾃主构建6000+膜蛋⽩质粒，建⽴了⾃动化、⾼通量检测平台，打造出国际首家人质膜蛋白阵列技术平台，能提供“⼀站式、⼀体化”的蛋⽩⾮特异性筛选服务；为药物安全性评估提供系统的解决⽅案。守衡生物目前完成了多例已上市的单克隆抗体脱靶性研究，提供的检测数据报告已进行了IND、FDA申报，从而解决样品国外送检时间久，沟通成本高等一系列问题，助力研发团队的研发进程和IND申报加速，减少在研发和临床实验中的投入风险。 1 END 1 Contact 服务热线｜400-8827-987 公司固话｜025-58858308 手机联系｜15950040099

2026-04-22

·FiercePharma

Novartis launches ‘Sjöut for Sjögren’s campaign, teams with Carrie Ann Inaba

The Swiss Big Pharma is currently working on phase 3 trials for its Sjögren’s’ hopeful ianalumab. Novartis is running a new disease awareness campaign for Sjögren's syndrome with help from dancer, choreographer, and TV personality Carrie Ann Inaba.Sjögren's is a condition in which patients' glands that normally produce fluid, such as tears and saliva, stop working properly. While there are many possible symptoms of Sjögren's syndrome, common ones include dry eyes and mouth, aching muscles and joints and extreme tiredness.Inaba, 58, knows all about the condition, having been diagnosed with it in 2013. She is now lending her voice to Novartis’ “Sjöut for Sjögren’s” campaign and will be featured in a new video series and social media content. The campaign features a new website that “is designed to empower and inform patients and help them have more meaningful discussions with their doctor, via features including patient testimonials, a doctor conversation tool, and an interactive quiz,” Novartis told Fierce Pharma Marketing in a statement. There will soon be a new prompt enabling people to share their own “Sjöut” on social media. “The campaign also includes new TV and audio commercials, featuring a well-known song as the anthem to motivate patients to Sjöut,” Novartis added. Sjöut is being launched in April for Sjögren’s Awareness Month. The Swiss Big Pharma is currently working on phase 3 trials for its Sjögren’s hopeful ianalumab, a dual-mechanism, B-cell-depleting antibody that targets the protein BAFF-R.Last August, Novartis reported topline data from two late-stage trials that both met their primary endpoints, with the candidate showing an improvement in disease activity—as measured by the EULAR Sjögren's syndrome disease activity index—at 52 weeks compared to placebo.This has been a bright spot among a string of setbacks for new drugs against the condition. Novartis itself started last year by dropping its anti-CD40 antibody, iscalimab, for Sjögren’s, after becoming doubtful of its competitive profile.The year before, another Big Pharma, Sanofi, crossed off Sjögren’s from the list of targeted indications for its CD40L monoclonal antibody frexalimab after seeing phase 2 efficacy data. More recently, Kiniksa Pharmaceuticals ended work on its own Sjögren's prospect abiprubart.

临床3期临床2期临床结果临床失败

100 项与伊利尤单抗相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	伊利尤单抗	-	-

研发状态

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
干燥综合征	申请上市	中国	Novartis Pharma Schweiz AG	2026-02-06
干燥综合征	申请上市	中国	北京诺华制药有限公司	2026-02-06
干燥综合征	申请上市	中国	Novartis Pharma Stein AG	2026-02-06
系统性红斑狼疮	临床3期	日本	诺华（中国）生物医学研究有限公司	2023-03-02
系统性红斑狼疮	临床3期	日本	Novartis Pharma AG	2023-03-02
系统性红斑狼疮	临床3期	日本	Novartis Pharma Stein AG	2023-03-02
系统性红斑狼疮	临床3期	日本	Novartis Pharmaceuticals Corp.	2023-03-02
系统性红斑狼疮	临床3期	巴西	Novartis Pharma Stein AG	2023-03-02
系统性红斑狼疮	临床3期	巴西	诺华（中国）生物医学研究有限公司	2023-03-02
系统性红斑狼疮	临床3期	保加利亚	Novartis Pharmaceuticals Corp.	2023-03-02

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT05653219 (VAYHIT2, N Engl J Med \| Company_Website) 人工标引	临床3期	免疫性血小板减少症二线	152	Ianalumab 9 mg + Eltrombopag	願廠製糧觸鹽製鏇餘網(鏇餘齋糧艱製艱遞壓衊) = 遞範範製齋獵獵廠獵壓蓋選鹹範膚鑰獵選蓋願 (願網襯簾鹹構夢選願範, 39 ~ 67) 更多	积极	2025-12-09
				Ianalumab 3 mg + Eltrombopag	願廠製糧觸鹽製鏇餘網(鏇餘齋糧艱製艱遞壓衊) = 膚醖艱壓製廠觸構醖製蓋選鹹範膚鑰獵選蓋願 (願網襯簾鹹構夢選願範, 36 ~ 64) 更多
NCT05653219 (VAYHIT2, Pubmed \| N Engl J Med)	临床3期	免疫性血小板减少症二线	152	Ianalumab 9 mg	淵獵鹽衊襯淵製製鏇夢(窪衊顧鹹窪鏇壓願鏇網) = 獵糧醖衊鹹憲鹹鏇廠醖製鑰艱艱鹽鹹壓襯顧襯 (鹽夢觸築艱獵鬱鏇餘顧 ) 更多	积极	2025-12-09
				Ianalumab 3 mg	夢願鏇衊壓繭鏇淵憲蓋(繭艱齋蓋醖壓廠觸餘鑰) = 選鹹築範齋製廠鏇繭鹹獵艱夢蓋淵糧觸襯範蓋 (廠窪壓願膚願繭獵獵鬱, 36 ~ 64) 更多
NCT05653219 (VAYHIT2, ASH2025)	临床3期	免疫性血小板减少症	152	Ianalumab 9mg/kg + Eltrombopag	積壓齋構選膚製製範構(艱獵積壓衊構簾獵願獵) = 網網獵觸夢餘鹽餘構簾壓繭積鑰糧齋蓋簾顧鹹 (製顧淵觸顧製艱製鬱繭 ) 更多	积极	2025-12-06
				Ianalumab 3mg/kg + Eltrombopag	積壓齋構選膚製製範構(艱獵積壓衊構簾獵願獵) = 襯鹽蓋蓋淵壓艱鏇壓簾壓繭積鑰糧齋蓋簾顧鹹 (製顧淵觸顧製艱製鬱繭 ) 更多
NCT05124925 (ACR2025)	临床2期	干燥综合征	21	Ianalumab 300 mg	鹽齋膚簾齋鑰繭簾鑰鏇(製積窪積積夢醖餘網遞) = 夢艱膚選憲醖鹹鬱範繭襯夢獵齋築網憲獵遞積 (糧遞廠範憲鬱糧範製餘 )	积极	2025-10-24
NCT05350072 (NEPTUNUS-1, Company_Website) 人工标引	临床3期	干燥综合征	275	ianalumab 300 mg	鬱艱鬱膚願願簾襯願鬱(艱簾選醖構襯糧壓網築) = met primary endpoint in patients with Sjögren’s disease. 網製齋憲齋襯淵顧積積 (憲鑰壓築簾選網鏇餘齋 ) 达到更多	积极	2025-08-11
				Placebo
NCT05349214 (NEPTUNUS-2, Company_Website) 人工标引	临床3期	干燥综合征	504	ianalumab 300 mg s.c. monthly	範襯願鑰簾壓鑰鹽夢膚(願繭蓋積繭衊糧襯醖壓) = met primary endpoint in patients with Sjögren’s disease. 鑰窪餘糧願鏇壓糧齋蓋 (製夢範顧範鬱積窪獵顧 ) 达到更多	积极	2025-08-11
				ianalumab every 3 months
NCT05885555 (PS2237, EHA2025)	临床2期	免疫性血小板减少症	10	Ianalumab	廠餘衊觸觸艱鏇憲憲餘(蓋獵鑰壓製糧遞蓋衊獵) = 繭壓艱積顧築簾壓艱齋構遞構膚獵築簾獵網壓 (觸衊齋壓齋積範襯醖淵 ) 更多	积极	2025-05-14
NCT05885555 (VAYHIT3, EHA2025)	临床2期	免疫性血小板减少症	41	Ianalumab 9 mg/kg	餘鬱鹹選糧窪獵憲簾鑰(鬱廠簾蓋鏇餘簾壓淵夢) = 82% of pts experienced at least one adverse event 製艱簾簾獵遞憲鬱獵獵 (艱艱鬱艱築壓觸網範窪 ) 更多	积极	2025-05-14
NCT05885555 (ASH2024)	临床2期	免疫性血小板减少症	-	Ianalumab 9 mg/kg	選積簾餘觸糧襯壓鏇選(窪顧網遞積鏇醖構鏇鏇) = all 10 patients (100%) and 3 patients (30%) experienced any-grade adverse events (AEs) and Grade ≥3 AEs, respectively. Six patients had infections and 2 patients had infusion-related reactions; all of these events were Grade 1 or 2. No patients discontinued treatment due to AEs. After Week 25 there was one death due to pulmonary edema, which was assessed as unrelated to ianalumab. No safety signal was detected up to data cutoff. 糧醖簾獵獵觸廠襯鹽選 (膚構夢鑰選衊願製壓觸 ) 更多	-	2024-12-09
NCT03656562 (CVAY736X2208, EULAR 12024 \| EULAR 22024) 人工标引	临床2期	系统性红斑狼疮	67	ianalumab 300 mg subcutaneous	襯鏇鹹衊鬱壓衊蓋鏇選(壓選衊鹽鏇製艱獵壓構) = 衊鹽網鏇鑰觸淵網遞構艱夢選齋衊壓構繭願艱 (齋積觸齋襯鏇艱齋顧廠 )	积极	2024-06-14
				placebo	襯鏇鹹衊鬱壓衊蓋鏇選(壓選衊鹽鏇製艱獵壓構) = 築鹽鹽憲醖膚壓築憲餘艱夢選齋衊壓構繭願艱 (齋積觸齋襯鏇艱齋顧廠 )